Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | ATPase/histidine kinase/DNA gyrase B/HSP90 domain-containing protein | 0.0192 | 0 | 0.5 |
Schistosoma mansoni | pyruvate dehydrogenase | 0.0474 | 1 | 1 |
Leishmania major | developmentally regulated phosphoprotein-like protein | 0.0474 | 1 | 0.5 |
Echinococcus multilocularis | Pyruvate dehydrogenase (lipoamide) kinase | 0.0474 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0474 | 1 | 0.5 |
Trypanosoma brucei | developmentally regulated phosphoprotein | 0.0474 | 1 | 0.5 |
Echinococcus multilocularis | Pyruvate dehydrogenase (lipoamide) kinase | 0.0474 | 1 | 0.5 |
Echinococcus granulosus | Pyruvate dehydrogenase lipoamide kinase | 0.0474 | 1 | 0.5 |
Trypanosoma cruzi | developmentally regulated phosphoprotein, putative | 0.0474 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Amnesia reversal (functional) | = 0 % | Ability to reverse electroconvulsive shock (ECS) induced amnesia in mice, after administering intraperitoneally, at a dose of 5 mg/kg | ChEMBL. | 6716406 |
Amnesia reversal (functional) | = 0 % | Ability to reverse electroconvulsive shock induced amnesia in mice, after administering intraperitoneally at a dose of 20 mg/kg | ChEMBL. | 6716406 |
Amnesia reversal (functional) | = 0 % | Ability to reverse electroconvulsive shock (ECS) induced amnesia in mice, after administering intraperitoneally, at a dose of 5 mg/kg | ChEMBL. | 6716406 |
Amnesia reversal (functional) | = 0 % | Ability to reverse electroconvulsive shock induced amnesia in mice, after administering intraperitoneally at a dose of 20 mg/kg | ChEMBL. | 6716406 |
Amnesia reversal (functional) | = 56 % | Ability to reverse electroconvulsive shock (ECS) induced amnesia in mice, after administering intraperitoneally, at a dose of 80 mg/kg | ChEMBL. | 6716406 |
Amnesia reversal (functional) | = 56 % | Ability to reverse electroconvulsive shock (ECS) induced amnesia in mice, after administering intraperitoneally, at a dose of 80 mg/kg | ChEMBL. | 6716406 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.